345 related articles for article (PubMed ID: 15578094)
1. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.
Gong B; Vitolo OV; Trinchese F; Liu S; Shelanski M; Arancio O
J Clin Invest; 2004 Dec; 114(11):1624-34. PubMed ID: 15578094
[TBL] [Abstract][Full Text] [Related]
2. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
Trinchese F; Liu S; Battaglia F; Walter S; Mathews PM; Arancio O
Ann Neurol; 2004 Jun; 55(6):801-14. PubMed ID: 15174014
[TBL] [Abstract][Full Text] [Related]
3. Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats.
Xu B; Li XX; He GR; Hu JJ; Mu X; Tian S; Du GH
Eur J Pharmacol; 2010 Feb; 627(1-3):99-105. PubMed ID: 19857483
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease is a synaptic failure.
Selkoe DJ
Science; 2002 Oct; 298(5594):789-91. PubMed ID: 12399581
[TBL] [Abstract][Full Text] [Related]
5. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
[TBL] [Abstract][Full Text] [Related]
6. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
Adlard PA; Cherny RA; Finkelstein DI; Gautier E; Robb E; Cortes M; Volitakis I; Liu X; Smith JP; Perez K; Laughton K; Li QX; Charman SA; Nicolazzo JA; Wilkins S; Deleva K; Lynch T; Kok G; Ritchie CW; Tanzi RE; Cappai R; Masters CL; Barnham KJ; Bush AI
Neuron; 2008 Jul; 59(1):43-55. PubMed ID: 18614028
[TBL] [Abstract][Full Text] [Related]
7. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI
Neuroscience; 2006 Sep; 141(3):1149-62. PubMed ID: 16753269
[TBL] [Abstract][Full Text] [Related]
8. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
[TBL] [Abstract][Full Text] [Related]
9. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms.
Costa DA; Cracchiolo JR; Bachstetter AD; Hughes TF; Bales KR; Paul SM; Mervis RF; Arendash GW; Potter H
Neurobiol Aging; 2007 Jun; 28(6):831-44. PubMed ID: 16730391
[TBL] [Abstract][Full Text] [Related]
10. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.
Savonenko A; Xu GM; Melnikova T; Morton JL; Gonzales V; Wong MP; Price DL; Tang F; Markowska AL; Borchelt DR
Neurobiol Dis; 2005 Apr; 18(3):602-17. PubMed ID: 15755686
[TBL] [Abstract][Full Text] [Related]
11. IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway.
Gong B; Pan Y; Zhao W; Knable L; Vempati P; Begum S; Ho L; Wang J; Yemul S; Barnum S; Bilski A; Gong BY; Pasinetti GM
Mol Immunol; 2013 Dec; 56(4):619-29. PubMed ID: 23911420
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
13. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of S14G-humanin against beta-amyloid induced LTP inhibition in mouse hippocampal slices.
Zhang W; Miao J; Hao J; Li Z; Xu J; Liu R; Cao F; Wang R; Chen J; Li Z
Peptides; 2009 Jun; 30(6):1197-202. PubMed ID: 19463756
[TBL] [Abstract][Full Text] [Related]
15. Arginine vasopressin prevents amyloid beta protein-induced impairment of long-term potentiation in rat hippocampus in vivo.
Jing W; Guo F; Cheng L; Zhang JF; Qi JS
Neurosci Lett; 2009 Feb; 450(3):306-10. PubMed ID: 19059464
[TBL] [Abstract][Full Text] [Related]
16. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy.
Breyhan H; Wirths O; Duan K; Marcello A; Rettig J; Bayer TA
Acta Neuropathol; 2009 Jun; 117(6):677-85. PubMed ID: 19387667
[TBL] [Abstract][Full Text] [Related]
17. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus.
Yamin G
J Neurosci Res; 2009 Jun; 87(8):1729-36. PubMed ID: 19170166
[TBL] [Abstract][Full Text] [Related]
18. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling.
Vitolo OV; Sant'Angelo A; Costanzo V; Battaglia F; Arancio O; Shelanski M
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13217-21. PubMed ID: 12244210
[TBL] [Abstract][Full Text] [Related]
19. Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice.
Gureviciene I; Ikonen S; Gurevicius K; Sarkaki A; van Groen T; Pussinen R; Ylinen A; Tanila H
Neurobiol Dis; 2004 Mar; 15(2):188-95. PubMed ID: 15006688
[TBL] [Abstract][Full Text] [Related]
20. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
